vimarsana.com

Page 3 - பெர்ன் பல்கலைக்கழகம் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ADA 2021 Roundup: SoliMix Trial; Byetta for Teens; Driving in Hypoglycemia

email article Below are a few more research highlights. SoliMix Trial When managing type 2 diabetes, the once-daily iGlarLixi (Soliqua) edged out the twice-daily premix insulin analog BIAsp 30, according to the SoliMix trial. The 26-week, open-label trial included adults with poorly controlled type 2 diabetes, defined as a baseline HbA1c between 7.5% and 10%. All participants were on basal insulin, as well as oral antidiabetic agents. Approved in 2016, iGlarLixi is a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and the GLP-1 receptor agonist lixisenatide (Lixi). BIAsp 30 is biphasic insulin aspart 30/70, and is a premixed injectable insulin analogue with 30% soluble, rapid-acting insulin aspart plus 70% intermediate-acting protamine-bound aspart.

Anticoagulation should not be regarded as primary cause of intracerebral haemorrhages, finds study

Anticoagulation should not be regarded as primary cause of intracerebral haemorrhages, finds study Cardiovascular diseases are usually complex and affect multiple organs simultaneously. Treatments for vascular diseases in the brain may therefore have implications for the treatment of cardiac diseases. It is therefore important to understand the respective causes and effects. This study explores the causes of intracerebral haemorrhages and links them to the risk of stroke associated with atrial fibrillation. It suggests a fundamental new assessment of the effects of blood thinning on intracerebral haemorrhages. About 1,000 patients with intracerebral haemorrhage are treated at stroke units each year in Switzerland. Intracerebral haemorrhages are more often fatal than other forms of strokes, and their incidence has not decreased in the past 30 years. The use of blood thinners was previously considered not only to be a risk factor but potential cause for a intracerebral haemorrhage.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.